Saccharomyces boulardii 用于 Antibiotic-Associated Diarrhea (AAD)
AMultiple meta-analyses show S. boulardii reduces AAD risk by 47-53% (RR 0.47). Most studied probiotic for AAD prevention with consistent positive results across antibiotic classes.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dsaccharomyces\u002Dboulardii\u0026condition\u003Dantibiotic\u002Dassociated\u002Ddiarrhea';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
A
结论
Multiple meta-analyses show S. boulardii reduces AAD risk by 47-53% (RR 0.47). Most studied probiotic for AAD prevention with consistent positive results across antibiotic classes.
Key Study Findings
Review
The evidence for probiotics in the treatment of digestive disorders in the pediatric population.
Dose: None
vs: None
Outcome: None
效果: None
None
研究人群: Pediatric population
Review
Intestinal Dysbiosis: Exploring Definition, Associated Symptoms, and Perspectives for a Comprehensive Understanding - a Scoping …
Dose: None
vs: None
Outcome: None
效果: None
None
研究人群: scoping review of intestinal dysbiosis definition, symptoms, and probiotic adjuvant therapy in adults and children
Other
Ibero-Latin American clinical practice guideline for the use of biotics in pediatric gastroenterology, hepatology, and …
Dose: None
vs: None
Outcome: Clinical guideline recommendations for pediatric GI
效果: None
None
研究人群: Pediatric patients with GI disorders
Observational Study
n=279
Use of Probiotics During Antibiotic Therapy in Pediatrics: A Cross-Sectional Survey of Italian Primary Care …
Dose: None
vs: None
Outcome: Probiotic prescribing habits of Italian PCPs
效果: L. rhamnosus GG used by 91.8%
None
研究人群: Italian primary care pediatricians
Randomized Controlled Trial
n=564
20 weeks
Double-blind
High-dose Probiotic Mix of Lactobacillus spp., Bifidobacterium spp., Bacillus coagulans, and Saccharomyces boulardii to Prevent …
Dose: None
vs: Placebo
Outcome: Quality of life
效果: None
P < .001
研究人群: None
Review
Clostridioides difficile Infections: Prevention and Treatment Strategies.
Dose: None
vs: None
Outcome: C. difficile infection treatment outcomes
效果: None
None
研究人群: Patients with C. difficile infection
Key Statistics
25
研究数量
5000
受试者
↑
Positive
A
等级
Referenced Papers
Probiotics and antimicrobial …
2025
26 次引用
The evidence for probiotics in the treatment of digestive disorders in the pediatric population.
Review
Journal of gastroenterology …
2025
10 次引用
Antibiotics (Basel, Switzerland)
2025
Boletin medico del …
2025
Open forum infectious …
2024
7 次引用
Zhongguo dang dai …
2024
5 次引用
Advances in experimental …
2024
2 次引用
Therapeutic advances in …
2023
97 次引用
Overview of systematic reviews of probiotics in the prevention and treatment of antibiotic-associated diarrhea in children.
Systematic Review
Frontiers in pharmacology
2023
20 次引用
Cureus
2023
19 次引用
Cureus
2023
5 次引用
The Journal of …
2023
1 次引用
Archivos argentinos de …
2022
23 次引用
Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infections.
Review
World journal of …
2019
92 次引用
Advances in experimental …
2019
17 次引用
Frontiers in medicine
2018
450 次引用
Choosing an appropriate probiotic product for your patient: An evidence-based practical guide.
Systematic Review
PloS one
2018
205 次引用
Pharmacological research
2018
132 次引用
World journal of …
2018
52 次引用
The American journal …
2018
46 次引用
World journal of …
2017
68 次引用
Journal of pediatric …
2016
233 次引用
Clinical and experimental …
2016
82 次引用
Open forum infectious …
2016
58 次引用
Digestive diseases (Basel, …
2016
37 次引用
The Cochrane database …
2015
233 次引用
Antibiotics (Basel, Switzerland)
2015
104 次引用
Journal of clinical …
2015
35 次引用
Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children.
Review
Nutrition in clinical …
2015
31 次引用
Nutricion hospitalaria
2015
5 次引用
MMW Fortschritte der …
2014
14 次引用
MMW Fortschritte der …
2014
3 次引用
Expert opinion on …
2014
The American journal …
2012
104 次引用
Saccharomyces boulardii and antibiotic-associated diarrhea: effectiveness of prophylactic use.
Other
The American journal …
2012
5 次引用
Medycyna wieku rozwojowego
2012
1 次引用
Journal of clinical …
2011
432 次引用
World journal of …
2010
512 次引用
Journal for specialists …
2010
22 次引用
Probiotics.
Review
American journal of …
2010
European journal of …
2009
91 次引用
Current opinion in …
2009
82 次引用
Advances in biochemical …
2008
535 次引用
Journal of clinical …
2008
Probiotics.
Review
American family physician
2008
The Journal of …
2007
265 次引用
The Cochrane database …
2007
The American journal …
2006
918 次引用
Probiotics for pediatric antibiotic-associated diarrhea: a meta-analysis of randomized placebo-controlled trials.
Meta-Analysis
CMAJ : Canadian …
2006
197 次引用
Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea.
Review
Journal of clinical …
2006
112 次引用
Medical science monitor …
2006
The American journal …
2001
648 次引用
International journal of …
2000
181 次引用
Clinical infectious diseases …
1998
346 次引用
Anaerobe
1997
40 次引用
Gastroenterology
1989
418 次引用
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
常用剂量
- general:
- 250-500 mg/day (equivalent to 5-10 billion CFU)
- aadprevention:
- 500 mg/day (start with antibiotic, continue 7 days after)
- cdiffprevention:
- 500 mg twice daily as adjunct to standard therapy
- travelersdiarrhea:
- 250-500 mg/day starting 5 days before travel
上限： Well-tolerated up to 1,000 mg/day in clinical trials
研究中使用的剂量
| 剂量 | 持续时间 | 效果 | N |
|---|---|---|---|
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Mixed | 279 |
| None | 20 weeks | Positive | 564 |
| None | -- | Positive | -- |
| None | 1 weeks | Positive | 47 |
| Various probiotic interventions | -- | Positive | -- |
最佳服用时间： Can be taken with or without food; space 2 hours from antifungals
Safety & Side Effects
已报告的副作用
- ⚠ Mild gas and bloating
- ⚠ Rare: fungemia in critically ill patients with central venous catheters
- ⚠ Thirst (yeast may increase water requirements)
- ⚠ Very rare: potential environmental contamination risk in ICU settings
已知相互作用
- ● Antifungal medications (may kill S. boulardii, reducing effectiveness)
- ● Monoamine oxidase inhibitors (S. boulardii contains tyramine)
- ● Immunosuppressants (theoretical risk of fungemia in immunocompromised patients)
可耐受最高摄入量： Well-tolerated up to 1,000 mg/day in clinical trials
在开始服用任何补充剂之前，请务必咨询您的医疗保健提供者。
Frequently Asked Questions
Does Saccharomyces boulardii help with Antibiotic-Associated Diarrhea (AAD)?
Based on 25 studies with 5,000 participants, there is strong evidence from multiple clinical trials that Saccharomyces boulardii may support Antibiotic-Associated Diarrhea (AAD) management. Our evidence grade is A (Strong Evidence).
How much Saccharomyces boulardii should I take for Antibiotic-Associated Diarrhea (AAD)?
Studies have used various dosages. A commonly studied range is 250-500 mg/day (equivalent to 5-10 billion CFU). Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Saccharomyces boulardii?
Reported side effects may include Mild gas and bloating, Rare: fungemia in critically ill patients with central venous catheters, Thirst (yeast may increase water requirements), Very rare: potential environmental contamination risk in ICU settings. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Saccharomyces boulardii and Antibiotic-Associated Diarrhea (AAD)?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 25 peer-reviewed studies with 5,000 total participants. The overall direction of effect is positive.
Related Evidence
其他成分用于 Antibiotic-Associated Diarrhea (AAD)
Saccharomyces boulardii 用于其他健康状况
FDA 免责声明: 这些声明未经美国食品药品监督管理局（FDA）评估。本网站上的产品和信息无意用于诊断、治疗、治愈或预防任何疾病。所展示的证据等级基于我们对已发表的同行评审研究的分析，不构成医疗建议。在开始任何补充剂方案之前，请务必咨询您的医疗保健提供者。